VaxGen Inc. said a story in the March 26, 2003, issue of BioWorld Today on AIDS vaccines should have said that its AidsVax B/B protein-based vaccine, which targets two strains of HIV subtype B, was studied in more than 5,000 volunteers from the U.S., Canada and the Netherlands. That study was not in partnership with the HIV Vaccine Trials Network. Also, an ongoing Phase II trial, studying AidsVax B/E in 2,500 injection drug abusers in Thailand, continues in partnership with the Thai government. Results from the latter are expected late this summer or fall. A Phase III prime-boost trial involving 15,000 Thai volunteers is not yet under way.
Editor's note: The changes have been made in BioWorld Online.